The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.

Inclusion Criteria:

• History of cardiovascular (CV) disease, high CV risk, or estimated glomerular filtration rate (eGFR) ≥30 to <60 mL/min/1.73m^2
• Mean seated office SBP ≥140 mmHg and ≤170 mmHg
• 24-hour mean SBP ≥130 mmHg and ≤170 mmHg assessed by ABPM
• Must be on stable therapy with 2 to 4 classes of antihypertensive medications

Exclusion Criteria:

• Secondary hypertension
• Orthostatic hypotension
• Proteinuria >3 g/day
• Serum potassium >4.8 milliequivalents per liter (mEq/L)

Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU.

Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more.

Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.